1. Home
  2. NBY vs IKT Comparison

NBY vs IKT Comparison

Compare NBY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovaBay Pharmaceuticals Inc.

NBY

NovaBay Pharmaceuticals Inc.

HOLD

Current Price

$4.70

Market Cap

398.2M

Sector

N/A

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.97

Market Cap

201.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBY
IKT
Founded
2000
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
398.2M
201.3M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
NBY
IKT
Price
$4.70
$1.97
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$6.00
AVG Volume (30 Days)
2.4M
596.6K
Earning Date
11-07-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.47
N/A
Revenue
$10,302,000.00
N/A
Revenue This Year
$23.91
N/A
Revenue Next Year
$32.05
N/A
P/E Ratio
$188.84
N/A
Revenue Growth
390.34
N/A
52 Week Low
$0.46
$1.33
52 Week High
$6.47
$3.49

Technical Indicators

Market Signals
Indicator
NBY
IKT
Relative Strength Index (RSI) 71.86 69.43
Support Level $4.37 $1.56
Resistance Level $6.47 $2.05
Average True Range (ATR) 0.91 0.17
MACD 0.20 0.05
Stochastic Oscillator 67.06 75.36

Price Performance

Historical Comparison
NBY
IKT

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: